• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.鉴定蛋白磷酸酶 1 作为 LRRK2 磷酸化循环的调节剂。
Biochem J. 2013 Nov 15;456(1):119-28. doi: 10.1042/BJ20121772.
2
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.帕金森病激酶 LRRK2 的选择性抑制剂的表征。
Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6.
3
Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation.蛋白磷酸酶 2A 全酶调节富含亮氨酸重复激酶 2 的磷酸化和积累。
Neurobiol Dis. 2021 Sep;157:105426. doi: 10.1016/j.nbd.2021.105426. Epub 2021 Jun 16.
4
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.LRRK2 丝氨酸 955 和 973 的磷酸化被帕金森病突变和 LRRK2 药理学抑制所破坏。
J Neurochem. 2012 Jan;120(1):37-45. doi: 10.1111/j.1471-4159.2011.07537.x. Epub 2011 Nov 11.
5
Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.携带激酶修饰突变的LRRK2激酶活性与其在Ser910、935和Ser955位点的磷酸化之间缺乏相关性。
PLoS One. 2014 May 16;9(5):e97988. doi: 10.1371/journal.pone.0097988. eCollection 2014.
6
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.LRRK2 激酶活性的抑制导致 Ser(910)/Ser(935)去磷酸化,破坏 14-3-3 结合并改变细胞质定位。
Biochem J. 2010 Sep 15;430(3):405-13. doi: 10.1042/BJ20100784.
7
LRRK2 dephosphorylation increases its ubiquitination.富含亮氨酸重复激酶2(LRRK2)的去磷酸化增加其泛素化。
Biochem J. 2015 Jul 1;469(1):107-20. doi: 10.1042/BJ20141305. Epub 2015 May 5.
8
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.鉴定 TAE684 是一种强效的 LRRK2 激酶抑制剂。
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. doi: 10.1016/j.bmcl.2012.01.084. Epub 2012 Jan 28.
9
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.LRRK2 GTPase 功能障碍在帕金森病发病机制中的作用。
Biochem Soc Trans. 2012 Oct;40(5):1074-9. doi: 10.1042/BST20120093.
10
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.IκB 激酶家族在 Toll 样受体信号转导过程中使帕金森病激酶 LRRK2 磷酸化 Ser935 和 Ser910。
PLoS One. 2012;7(6):e39132. doi: 10.1371/journal.pone.0039132. Epub 2012 Jun 18.

引用本文的文献

1
14-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state.14-3-3蛋白结合可使帕金森相关激酶LRRK2维持在非活性状态。
Nat Commun. 2025 Aug 5;16(1):7226. doi: 10.1038/s41467-025-62337-1.
2
Leucine-rich repeat kinase 2 biomarkers for Parkinson's disease.帕金森病的富含亮氨酸重复激酶2生物标志物。
Biochem J. 2025 May 28;482(11):BCJ20253099. doi: 10.1042/BCJ20253099.
3
G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage.G2019S选择性LRRK2激酶抑制剂可消除线粒体DNA损伤。
NPJ Parkinsons Dis. 2024 Mar 1;10(1):49. doi: 10.1038/s41531-024-00660-y.
4
Post-translational modification and mitochondrial function in Parkinson's disease.帕金森病中的翻译后修饰与线粒体功能
Front Mol Neurosci. 2024 Jan 11;16:1329554. doi: 10.3389/fnmol.2023.1329554. eCollection 2023.
5
PAK6-mediated phosphorylation of PPP2R2C regulates LRRK2-PP2A complex formation.PAK6介导的PPP2R2C磷酸化调节LRRK2-PP2A复合物的形成。
Front Mol Neurosci. 2023 Dec 18;16:1269387. doi: 10.3389/fnmol.2023.1269387. eCollection 2023.
6
LRRK2 is involved in the chemotaxis of neutrophils and differentiated HL-60 cells, and the inhibition of LRRK2 kinase activity increases fMLP-induced chemotactic activity.LRRK2 参与中性粒细胞和分化的 HL-60 细胞的趋化作用,抑制 LRRK2 激酶活性可增加 fMLP 诱导的趋化活性。
Cell Commun Signal. 2023 Oct 30;21(1):300. doi: 10.1186/s12964-023-01305-y.
7
Leucine-rich repeat kinase 2 at a glance.富含亮氨酸重复激酶 2 速览。
J Cell Sci. 2023 Sep 1;136(17). doi: 10.1242/jcs.259724. Epub 2023 Sep 12.
8
Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.LRRK2 基因突变在帕金森病中的作用概述。
Biomolecules. 2023 May 16;13(5):845. doi: 10.3390/biom13050845.
9
Impact of Type II LRRK2 inhibitors on signaling and mitophagy.LRRK2 型抑制剂对信号转导和线粒体自噬的影响。
Biochem J. 2021 Oct 15;478(19):3555-3573. doi: 10.1042/BCJ20210375.
10
Abrogation of LRRK2 dependent Rab10 phosphorylation with TLR4 activation and alterations in evoked cytokine release in immune cells.TLR4 激活导致 LRRK2 依赖性 Rab10 磷酸化的消除,以及免疫细胞中诱发性细胞因子释放的改变。
Neurochem Int. 2021 Jul;147:105070. doi: 10.1016/j.neuint.2021.105070. Epub 2021 May 15.

本文引用的文献

1
Phosphorylation of LRRK2: from kinase to substrate.LRRK2 的磷酸化:从激酶到底物。
Biochem Soc Trans. 2012 Oct;40(5):1102-10. doi: 10.1042/BST20120128.
2
Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.采用高通量 TR-FRET 细胞测定法检测 LRRK2 Ser935 磷酸化筛选新型 LRRK2 抑制剂。
PLoS One. 2012;7(8):e43580. doi: 10.1371/journal.pone.0043580. Epub 2012 Aug 28.
3
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.IκB 激酶家族在 Toll 样受体信号转导过程中使帕金森病激酶 LRRK2 磷酸化 Ser935 和 Ser910。
PLoS One. 2012;7(6):e39132. doi: 10.1371/journal.pone.0039132. Epub 2012 Jun 18.
4
The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.与帕金森病相关的富含亮氨酸重复激酶 2 的 G2385R 变异是一种部分功能丧失的突变。
Biochem J. 2012 Aug 15;446(1):99-111. doi: 10.1042/BJ20120637.
5
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.帕金森病遗传学的综合研究综述和系统荟萃分析:PDGene 数据库。
PLoS Genet. 2012;8(3):e1002548. doi: 10.1371/journal.pgen.1002548. Epub 2012 Mar 15.
6
LRRK2 Parkinson disease mutations enhance its microtubule association.LRRK2 帕金森病突变增强其与微管的结合。
Hum Mol Genet. 2012 Feb 15;21(4):890-9. doi: 10.1093/hmg/ddr526. Epub 2011 Nov 11.
7
What genetics tells us about the causes and mechanisms of Parkinson's disease.遗传学告诉我们帕金森病的病因和发病机制。
Physiol Rev. 2011 Oct;91(4):1161-218. doi: 10.1152/physrev.00022.2010.
8
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.LRRK2 丝氨酸 955 和 973 的磷酸化被帕金森病突变和 LRRK2 药理学抑制所破坏。
J Neurochem. 2012 Jan;120(1):37-45. doi: 10.1111/j.1471-4159.2011.07537.x. Epub 2011 Nov 11.
9
The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease.激酶 LRRK2 是转录因子 NFAT 的调节剂,可调节炎症性肠病的严重程度。
Nat Immunol. 2011 Oct 9;12(11):1063-70. doi: 10.1038/ni.2113.
10
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.LRRK2 外显子变异与帕金森病易感性的关联:一项病例对照研究。
Lancet Neurol. 2011 Oct;10(10):898-908. doi: 10.1016/S1474-4422(11)70175-2. Epub 2011 Aug 30.

鉴定蛋白磷酸酶 1 作为 LRRK2 磷酸化循环的调节剂。

Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.

机构信息

*Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Kapucijnenvoer 33, 3000 Leuven, Belgium.

出版信息

Biochem J. 2013 Nov 15;456(1):119-28. doi: 10.1042/BJ20121772.

DOI:10.1042/BJ20121772
PMID:23937259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5141581/
Abstract

A cluster of phosphorylation sites in LRRK2 (leucine-rich repeat kinase 2), including Ser910, Ser935, Ser955 and Ser973, is important for PD (Parkinson's disease) pathogenesis as several PD-linked LRRK2 mutants are dephosphorylated at these sites. LRRK2 is also dephosphorylated in cells after pharmacological inhibition of its kinase activity, which is currently proposed as a strategy for disease-modifying PD therapy. Despite this importance of LRRK2 dephosphorylation in mutant LRRK2 pathological mechanism(s) and in LRRK2's response to inhibition, the mechanism by which this occurs is unknown. Therefore we aimed to identify the phosphatase for LRRK2. Using a panel of recombinant phosphatases, we found that PP1 (protein phosphatase 1) efficiently dephosphorylates LRRK2 in vitro. PP1 activity on LRRK2 dephosphorylation was confirmed in cells using PP1 inhibition to reverse LRRK2 dephosphorylation induced by the potent LRRK2 kinase inhibitor LRRK2-IN1 as well as in R1441G mutant LRRK2. We also found that PP1 and LRRK2 can form a complex in cells. Furthermore, we observed that PP1 inhibition modulates LRRK2's cellular phenotype by reducing skein-like LRRK2-positive structures associated with dephosphorylation. In conclusion, the present study reveals PP1 as the physiological LRRK2 phosphatase, responsible for LRRK2 dephosphorylation observed in PD mutant LRRK2 and after LRRK2 kinase inhibition.

摘要

LRRK2(富含亮氨酸重复激酶 2)中的一组磷酸化位点,包括 Ser910、Ser935、Ser955 和 Ser973,对于 PD(帕金森病)发病机制很重要,因为几个 PD 相关的 LRRK2 突变体在这些位点被去磷酸化。LRRK2 的激酶活性被药理学抑制后,细胞内也会发生去磷酸化,目前这被提议作为一种改变 PD 治疗的疾病策略。尽管 LRRK2 去磷酸化在突变型 LRRK2 病理机制和 LRRK2 对抑制的反应中很重要,但发生这种情况的机制尚不清楚。因此,我们旨在确定 LRRK2 的磷酸酶。使用一组重组磷酸酶,我们发现 PP1(蛋白磷酸酶 1)在体外有效地使 LRRK2 去磷酸化。使用 PP1 抑制来逆转强效 LRRK2 激酶抑制剂 LRRK2-IN1 诱导的以及 R1441G 突变型 LRRK2 的 LRRK2 去磷酸化,在细胞中证实了 PP1 对 LRRK2 去磷酸化的活性。我们还发现 PP1 和 LRRK2 可以在细胞中形成复合物。此外,我们观察到 PP1 抑制通过减少与去磷酸化相关的扭曲状 LRRK2 阳性结构来调节 LRRK2 的细胞表型。总之,本研究揭示了 PP1 是 LRRK2 的生理磷酸酶,负责 PD 突变型 LRRK2 和 LRRK2 激酶抑制后观察到的 LRRK2 去磷酸化。